Safety and Tolerability of Octaplasma® in paediatrics
The safety of Octaplasma® has been extensively studied in adolescents and children.
Safety and Tolerability of Octaplasma® in Large volume Exchange
The safety of Octaplasma® has been extensively studied in large volume exchange.
Safety and Tolerability of Octaplasma® in paediatrics
No Severe Allergic Reactions and Improved Outcomes with Octaplasma in a variety of treatment settings®. 89% (16/18) of patients were switched to Octaplasma® due to an allergic reaction to FFP or CSP.
Consistent reduction in transfusion reactions over a decade post- switch to Octaplasma® in the UK
Consistent reduction in transfusion reactions over a decade post-switch to Octaplasma® in the UK
AABB: American Association of Blood Banks; CPB: cardiopulmonary bypass; CSP: cryosupernatant plasma; ICU: intensive care unit; TACO: Transfusion Associated Circulatory Overload; TRALI: transfusion-related acute lung injury; TTP: thrombotic thrombocytopenic purpura.
* Retrospective analysis of case notes, intraoperative, and laboratory data of 105 pediatric cardiac surgery patients over a 10-year period (January 2002–January 2012).2 [KALSI p.1328A]
† Retrospective review and analysis of case notes for 50 consecutive patient episodes of acute TTP treated between February 2003 and December 2005. 12 episodes were treated with CSP only, and 21 episodes were treated with Octaplasma® only. Primary endpoint was the number of PEX to remission.3 [SCULLY p.155A; p.155B; p.155C] ‡
Data from 2006–2012.
- Octaplasma® Product Monograph. Octapharma Canada Inc. October 31, 2022.
- Josephson CD, Goldstein S, Askenazi D, Cohn CS, Spinella P, Metjian A. Use of solvent/detergent-treated pooled plasma for therapeutic plasma Exchange in children. Poster.
- Spinella PC, Borasino S, Alten J. Solvent/detergent-treated plasma in the management of pediatric patients who require replacement of multiple coagulation factors: an open-label, multicenter, post-marketing study. Front Pediatr. 2020;8:572. doi: 10.3389/fped.2020.00572.
- Scully M, Longair I, Flynn M, Berryman J, Machin J. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang. 2007;93(2):154–158.
- SHOT. (2021). SHOT report 2021. [PDF]. Retrieved from https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked-V3-November.pdf
Explore
Offices
1000-25 King Street West,
Toronto, Ontario
CA M5L 1G1
Contact
info.canada@octapharma.com
+1(416) 531-5533
Octaplasma® is a registered trademark of Octapharma Canada Inc. All other trademarks are property of their respective owners.
